logo
Plus   Neg
Share
Email

Hikma Pharma Gets Rights To Commercialise 11 Of Chiesi's Products In Egypt

Hikma Pharmaceuticals PLC (HIK.L) has reached an exclusive licensing and distribution agreement with Chiesi Farmaceutici, which provides Hikma with exclusive rights to commercialise 11 of Chiesi's products in Egypt. These specialty products are primarily in respiratory and neonatal therapeutic areas.

Hikma Pharma said the new agreement, which builds on the company's existing partnership with Chiesi in Morocco, adds a range of products to the Egyptian portfolio, including Foster, Foster Nexthaler, Trimbow and Curosurf.

Chiesi Farmaceutici is a research-focused international pharmaceutical Group, headquartered in Italy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Safavieh LLC recalled about 760 units of Aura and Silas 3-Drawer Chests for possible serious tip-over and entrapment hazards that can result in death or injuries to children, the U.S. Consumer Product Safety Commission said in a statement. The company said the chests are unstable if they are not anchored to the wall. Shares of Standard Chartered Plc were losing around 4 percent in London trading after the bank warned on fiscal 2020 income growth mainly due to coronavirus impact. This was despite reporting a profit before tax in its fourth quarter, compared to last year's loss. For 2020, the company now expects income growth to be below its medium-term target range of 5 percent to 7 percent. A 2018 fatal crash involving a Tesla Inc. vehicle was likely caused by the car's autopilot system as well as distracted driving, according to a report by the National Transportation Safety Board or NTSB. The driver of the Tesla's Model X electric-powered sport utility vehicle, Walter Huang, was killed when it collided with a damaged crash attenuator on March 23, 2018 in Mountain View, California.
Follow RTT
>